Clinical case: idelalisib-induced immunoglobulin flare

Immunopharmacol Immunotoxicol. 2017 Aug;39(4):251-252. doi: 10.1080/08923973.2017.1318912. Epub 2017 May 19.

Abstract

IgM flare is a transient, treatment-induced, increase of monoclonal IgM levels in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) patients. Until recently this phenomenon was observed in patients treated with Cladribine and Rituximab. Here we report a case of a heavily pretreated chronic lymphocytic leukemia patient with an atypically high immunoglobulin production who developed clinically significant immunoglobulin flare following Idelalisib treatment.

Keywords: Idelalisib; chronic lymphocytic leukemia; complication; immunoglobulin flare; treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Cladribine / adverse effects
  • Cladribine / immunology*
  • Female
  • Humans
  • Immunoglobulin M / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Purines / adverse effects*
  • Quinazolinones / adverse effects*
  • Rituximab / adverse effects
  • Waldenstrom Macroglobulinemia / drug therapy
  • Waldenstrom Macroglobulinemia / immunology

Substances

  • Immunoglobulin M
  • Purines
  • Quinazolinones
  • Cladribine
  • Rituximab
  • idelalisib